Humasis Co. Ltd Asset Resilience Ratio
Humasis Co. Ltd asset resilience ratio. Humasis Co. Ltd (205470) has an Asset Resilience Ratio of 52.35% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Humasis Co. Ltd (205470) liquidity interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Humasis Co. Ltd (2016–2024)
Asset resilience ratio of Humasis Co. Ltd from 2016 to 2024. This chart shows how Humasis Co. Ltd's Asset Resilience Ratio has changed over time. Read 205470 liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Humasis Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Humasis Co. Ltd asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩177.84 Billion | 52.35% |
| Total Liquid Assets | ₩177.84 Billion | 52.35% |
Asset Resilience Insights
- Very High Liquidity: Humasis Co. Ltd maintains exceptional liquid asset reserves at 52.35% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Humasis Co. Ltd Industry Peers by Asset Resilience Ratio
Compare Humasis Co. Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shenzhen New Industries Biomedical
SHE:300832 |
Medical Devices | 9.95% |
|
Double Medical Technology Inc
SHE:002901 |
Medical Devices | 12.59% |
|
BMC Medical Co. Ltd. A
SHE:301367 |
Medical Devices | 44.96% |
|
Emvision Medical Devices Ltd
AU:EMV |
Medical Devices | 0.06% |
|
Hironic Co. Ltd
KQ:149980 |
Medical Devices | 17.42% |
|
DRGEM Corporation
KQ:263690 |
Medical Devices | 2.12% |
|
Oncosil Medical Ltd
AU:OSL |
Medical Devices | 0.00% |
|
Adherium Ltd
AU:ADR |
Medical Devices | 15.45% |
Humasis Co. Ltd Asset Resilience Ratio by Year (2016–2024)
Humasis Co. Ltd asset resilience ratio by year from 2016 to 2024. The table below shows the annual Asset Resilience Ratio data for Humasis Co. Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 58.65% | ₩194.68 Billion ≈ $131.93 Million |
₩331.92 Billion ≈ $224.93 Million |
-11.31pp |
| 2023-12-31 | 69.96% | ₩242.99 Billion ≈ $164.67 Million |
₩347.31 Billion ≈ $235.37 Million |
+1.80pp |
| 2022-12-31 | 68.16% | ₩318.69 Billion ≈ $215.97 Million |
₩467.53 Billion ≈ $316.84 Million |
+10.88pp |
| 2021-12-31 | 57.29% | ₩195.19 Billion ≈ $132.28 Million |
₩340.71 Billion ≈ $230.90 Million |
+23.65pp |
| 2020-12-31 | 33.64% | ₩22.99 Billion ≈ $15.58 Million |
₩68.35 Billion ≈ $46.32 Million |
-25.57pp |
| 2019-12-31 | 59.21% | ₩21.60 Billion ≈ $14.64 Million |
₩36.49 Billion ≈ $24.73 Million |
-1.64pp |
| 2018-12-31 | 60.85% | ₩20.87 Billion ≈ $14.14 Million |
₩34.29 Billion ≈ $23.24 Million |
+6.10pp |
| 2017-12-31 | 54.75% | ₩15.51 Billion ≈ $10.51 Million |
₩28.32 Billion ≈ $19.19 Million |
-45.03pp |
| 2016-12-31 | 99.78% | ₩12.10 Billion ≈ $8.20 Million |
₩12.13 Billion ≈ $8.22 Million |
-- |
About Humasis Co. Ltd
Humasis Co. Ltd. manufactures and sells pharmaceuticals and medical devices in South Korea and internationally. It offers immunodiagnostic kits, such as quantitative and qualitative tests, cardiac and cancer markers, infectious diseases, hormones, and women's health. The company also provides bio-material products, such as COVID-19 nucleocapsid protein, human immunodeficiency virus surface protei… Read more